The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...
The Lee Health Heart Institute recently hit a significant milestone—the team has performed more than 2,000 transcatheter aortic valve replacement (TAVR) procedures! The expert team of interventional ...
No one was more surprised than Dr. Rick Dearman when he was diagnosed with severe symptomatic aortic stenosis, also known as heart valve failure. As a heart surgeon, he’d treated hundreds of people ...
Bethesda Heart, part of Bethesda Heart Hospital East in Boynton Beach, Fla., has performed its 100th transcatheter aortic valve replacement in under two years since launching the TAVR program in March ...
Citi analyst Joanne Wuensch keeps a Buy rating on Edwards Lifesciences (EW) with an $81 price target after the company presented its EARLY TAVR clinical data, saying it came in better than expected ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback